Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
The UPC and the UP: impact on patent portfolios, co-ownership and licensing
UPC: Jurisdiction and opt-out
The UPC Rules
Implications for Benefit Plans of the End of the COVID-19 National Emergency and Public Health Emergency
On Monday, April 10, President Biden signed a congressional resolution immediately ending the COVID-19 National Emergency and he had previously announced …
Australian High Court smooths out wrinkle in trade mark law: Reputation not relevant to ‘deceptive similarity’ test of infringement
R&W Case Alert: Fraud-Based Claims Against Private Equity Firms
In recent years, private equity (PE) firms have bought and sold more businesses, at higher prices, than ever before. This growth has raised the stakes …
Cybersecurity, Privacy and Data Protection 2022 Year in Review
The year 2022 saw a groundswell of interest in privacy rights and related legislation. Five states enacted new laws or regulations aimed at protecting a …
SCOTUS Case With Implications for Attorney-Client Privilege Between CIPOs and C-Suite
Litigation associate Mark H. Russell co-authored an IAM article titled “SCOTUS Case With Implications for Attorney-Client Privilege Between CIPOs and …
Exploring The Amgen Genus Claims Headed To High Court
Intellectual Property associate Jeffrey Coleman co-authored a Law360 article titled “Exploring The Amgen Genus Claims Headed To High Court” on Jan. 10, …
NY DFS Issues Industry Letter on Health Outcomes and Disparities
New York health insurers are required to respond to a New York State Department of Financial Services (DFS) industry letter on health disparities and …
G20/B20: Can we avoid downside risks for the global economy?
Near enough is good enough: Full Federal Court of Australia revisits construction of “about” in patent claim
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane